Navigation Links
Mylan Schedules Financial Results Conference Call and Live Webcast for the Quarter and Nine Months Ended Dec. 31, 2007
Date:2/5/2008

Mylan to Present at Merrill Lynch's Global Pharmaceutical Conference Feb.

5, 2008

PITTSBURGH, Feb. 5 /PRNewswire-FirstCall/ -- Mylan Inc. (NYSE: MYL) announced today that it will host a conference call and live webcast on Wednesday, Feb. 27, 2008, at 10:30 a.m. ET to provide a review of the quarter and nine months ended Dec. 31, 2007. The Company also will provide an operational and integration update on Merck Generics, which the Company acquired on Oct. 2, 2007. The Company will release its financial results before the market opens.

The Company also announced that it will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference today, Feb. 5, at 11:40 a.m. ET. A copy of the Company's slide presentation will be available at http://www.mylan.com.

The dial-in number to access the Feb. 27 call is 877-874-1586 or 719-325- 4814 for international callers. A replay, available for approximately eight days, will be available at 888-203-1112 or 719-457-0820 for international callers, with access pass code 8774583.

To access a live webcast of the Feb. 27 call, please log on to Mylan's Web site (http://www.mylan.com) at least 15 minutes before the event is to begin to register and download or install any necessary software. A replay of the webcast will be available on http://www.mylan.com for approximately eight days.

Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.

For more information about Mylan, visit http://www.mylan.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Mylan Declares Quarterly Preferred Stock Dividend
2. Mylan Provides Update Relating to Ongoing Lorazepam and Clorazepate Litigation
3. Mylan Announces Final FDA Approval for Cetirizine Hydrochloride Tablets
4. Mylan Sets Date of 2008 Annual Meeting
5. Mylan Receives $26.2 Million From Exercise of Overallotment Option of Common Stock
6. Mylan Announces Tentative FDA Approval Under PEPFAR for Tenofovir Disoproxil Fumarate Tablets
7. Mylan Completes $2.89 Billion of Equity Financings, Including Exercise of Overallotment Option of Mandatory Convertible Preferred Stock
8. Mylan Prices Offerings of Common Stock and Mandatory Convertible Preferred Stock
9. Mylan Announces Appointment of Joseph F. Haggerty as Senior Vice President and Global General Counsel
10. Mylan Announces Settlement of Paroxetine Hydrochloride Extended-Release Tablets with GlaxoSmithKline
11. Mylan Settles Its First-to-File Opportunity on Levetiracetam with UCB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 2017 , ... Driving Dynamics Inc., announced today it has been selected as ... part of its mission to continually monitor the training marketplace for the best providers ... 20 Health and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... Spain’s popular line ... Laboratories, is coming soon to RonnieColemanNutrition.com. , ACPG Laboratories has been in ... trusted, well-respected brand reliant on the healing properties of plants, a proven science ...
(Date:9/19/2017)... Houston, TX (PRWEB) , ... September 19, 2017 , ... ... individual's risk of a heart attack by measuring their risk factors and calculating their ... Harvey and Irma were predicted the same way CVD is predicted today: an estimated ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... across the country with the Davidson Fellows Scholarship on September 27 at a ... projects in Science, Technology, Engineering, Mathematics, Literature and Music. , “I am honored ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... linked to the Certified Emergency Nurse (CEN®) certification according to a ... The value of certification study, conducted by the Human Resources Research Organization (HumRRO) ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017  Medical professionals are ... skills while treating their patients. Medical simulations ... without involving patients. Simulation provides a safe ... carry out procedures, refine techniques and build ... of new technology, such as augmented reality, ...
(Date:9/5/2017)... KEYSTONE, Colo. , Sept. 5, 2017 ... their XR-29 DoseCheck solution. Scannerside DoseCheck is a third-party ... update existing CT scanners and allows compliance with current ... The Sapheneia-Scannerside proprietary XR 29 DoseCheck solution is specifically ... notifications and alerts of potential radiation doses over a ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
Breaking Medicine Technology: